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ABSTRACT
Abiraterone acetate, a prodrug of the CYP17A1 inhibitor
abiraterone that blocks androgen biosynthesis, is approved for
treatment of patients with metastatic castration-resistant
prostate cancer (mCRPC) in combination with prednisone or
prednisolone5mgtwicedaily.This reviewevaluatesthebasis for
the effects of prednisone onmineralocorticoid-related adverse
events that arise because of CYP17A1 inhibition with abirater-
one. Coadministration with the recommended dose of gluco-
corticoid compensates for abiraterone-induced reductions in
serumcortisol andblocks the compensatory increase inadreno-
corticotropic hormone seen with abiraterone. Consequently,
5 mg prednisone twice daily serves as a glucocorticoid replace-
ment therapy when coadministered with abiraterone acetate,
analogous to use of glucocorticoid replacement therapy for
certain endocrine disorders. We searched PubMed to identify
safety concerns regarding glucocorticoid use, placing a focus
on longitudinal studies in autoimmune and inflammatory
diseases and cancer. In general, glucocorticoid-related adverse
events, including bone loss, immunosuppression, hyperglyce-
mia, mood and cognitive alterations, and myopathy, appear
dose related and tend to occur at doses and/or treatment
durations greater than the lowdose of glucocorticoid approved
in combination with abiraterone acetate for the treatment of
mCRPC. Although glucocorticoids are often used to manage
tumor-related symptoms or to prevent treatment-related
toxicity, available evidence suggests that prednisone and
dexamethasonemightalsooffermodest therapeuticbenefit in
mCRPC. Given recent improvements in survival achieved for
mCRPC with novel agents in combination with prednisone,
the risks of these recommended glucocorticoid doses must
be balanced with the benefits shown for these regimens.
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Implications for Practice: Abiraterone acetate, a prodrug of the CYP17A1 inhibitor abiraterone, suppresses testosterone and
cortisol production in patients with metastatic castration-resistant prostate cancer (mCRPC), but cortisol precursors with min-
eralocorticoid activity rise during abiraterone acetate monotherapy. Low-dose prednisone (5 mg twice daily) coadministration
serves as glucocorticoid replacement therapy, lowers adrenocorticotropic hormone, and reduces the incidence and severity of
mineralocorticoid-related adverse events. In contrast, pharmacologic glucocorticoid doses used to treat other malignancies and
autoimmune disorders are typically$20mg/day prednisone equivalence, and these higher doses are associated with an adverse
safety profile. The safety profile of low-dose glucocorticoid use in mCRPC deserves further study.
INTRODUCTION
The progression of metastatic castration-resistant prostate
cancer (mCRPC) despite androgen deprivation therapy and
castrate testosterone levels frequently reflects the continued
production of androgens in the adrenal glands and within
prostate tumor tissue [1, 2]. Abirateroneacetate is theprodrug
of abiraterone, which blocks androgen biosynthesis via in-
hibition of steroid 17-hydroxylase/17,20-lyase (cytochrome
P450c17 [CYP17A1]) [3]. Abiraterone acetate in combination
with prednisone or prednisolone at a low dose of 5 mg twice
daily has been shown to improve survival of mCRPC patients
previously treated with docetaxel and those who had not
received prior chemotherapy [4, 5]. The administration of
abiraterone acetate with glucocorticoids is necessary to
manage adverse events related to mineralocorticoid excess,
such as hypokalemia, hypertension, and fluid retention, which
can occur as a result of CYP17A1 inhibition [6–8]. This review
evaluates the basis for the remedial effects of low-dose
prednisone to prevent mineralocorticoid excess-related
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adverse events anticipated with abiraterone acetate therapy
and assesses safety concerns about glucocorticoid therapy
based on longitudinal studies conducted in autoimmune and
inflammatory diseases and cancer.
MATERIALS AND METHODS
We searched PubMed using the terms corticosteroids, gluco-
corticoids, steroids,abiraterone,prostatecancer, andmetastatic
castrate-resistant prostate cancer for clinical trials, reviews, and
case reports published in English without filtering for dates.
Information selected for this article was obtained from pre-
clinical investigations, early clinical trials, and phase III studies
that served as the basis for approval of prednisone with
abiraterone acetate in patients progressing after docetaxel
and without prior chemotherapy. A focus was placed on the
glucocorticoid literaturewith filtersofclinical trial, review, case
reports, and English describing longitudinal follow-up of the
prolonged therapeutic use of prednisone and its association
with autoimmune and inflammatory disease, malignant dis-
ease, bone abnormalities, hyperglycemia and diabetes, mood
and cognitive function, fatigue, and myopathy. Also included
were the effects of prednisone on immune function and the
therapeutic benefits and disadvantages of prednisone co-
administration in prostate cancer. Data from recent congress
presentations and publications known to the authors in-
dependent of this literature search were also incorporated.
We did not include in vitro data showing glucocorticoid
receptor stimulation of cancer growth or genes overlapping
with androgen receptor targets in CRPC because this
mechanism of driving disease progression has not been
established beyond preclinical models. AFFIRM data show-
ing increased risk of death and progression with baseline
glucocorticoid use independent of other prognostic factors
alsowerenot included [9]becauseprognosticmodels fromthe
COU-AA-301 trial did not validate this result. The latter
information is the subject of a separate line of investigation
which was published separately [10].
IMPACTOFBLOCKINGCYP17A1ONSYNTHESISOFADRENAL
STEROIDS BEYOND ANDROGENS
Abiraterone is a potent, selective, and irreversible inhibitor of
CYP17A1, a microsomal enzyme with 17a-hydroxylase and
C17,20-lyase activities that are required for androgen bio-
synthesis via both classic and backdoor pathways (Fig. 1) [3,
12]. Whereas androgen biosynthesis requires both of these
CYP17A1activities, cortisol biosynthesis requiresonly the17a-
hydroxylase activity of CYP17A1. The efficacy of abiraterone
in blocking androgen biosynthesis is shown by substantial
reductions in serum androgen levels (Fig. 2) [8, 13]. Use of
abiraterone to inhibit androgen synthesis, however, is asso-
ciated with several undesired physiologic changes, including a
decrease in cortisol levels and a compensatory increase in
adrenocorticotropic hormone (ACTH) [8, 13, 14]. This rise in
ACTH leads to accumulation of steroidswithmineralocorticoid
properties upstream of CYP17A1 in the cortisol biosynthetic
pathway (Fig. 3) and, ultimately, to mineralocorticoid-related
adverse events, including hypertension, hypokalemia, and fluid
retention [12].
Cortisol levels follow a circadian rhythm in which levels
are lowest at midnight, begin rising around 2–4 AM, peak
after waking, and then slowly return to their nadir [14].
Serum cortisol is regulated by its negative feedback on the
hypothalamic-pituitary axis: low cortisol stimulates release
of corticotropin-releasing hormone from the paraventricular
nucleus of the hypothalamus, which triggers ACTH release
from the anterior pituitary and, in turn, cortisol production in
the adrenal cortex. Healthy adults have a morning serum
cortisol level in the range of 5–23 mg/dL (138–635 nmol/L)
and midnight serum cortisol ,5 mg/dL (,138 nmol/L). In
studies of mCRPC patients, abiraterone reduced serum
cortisol to near the lower limit of the normal range [8] and
increased ACTH from a median of 17 pg/mL (range: ,9–50
pg/mL) toamedianof124pg/mL (range:46–370pg/mL) [13].
When coadministered with abiraterone acetate, low-dose
prednisone or prednisolone substitutes for cortisol, com-
pensating for the abiraterone-induced reduction in serum
cortisol (Fig. 4) [5, 15, 16]. Following this principle, the potent
glucocorticoid dexamethasone normalizes the abiraterone-
induced rise in ACTH (Fig. 5) [13]. Prednisolone or its
precursor prednisone is approximately four times more
potent as a glucocorticoid compared with cortisol [18].
Treatment of 15 mCRPC patients with abiraterone acetate
plus 10 mg prednisolone resulted in median prednisolone
plasma concentrations of 152 nM—equivalent to 608 nM
cortisol—thus providing physiologic glucocorticoid replace-
ment (Fig. 4) [16].At this dose, themineralocorticoid activityof
prednisolone is minimal [19].
Glucocorticoid replacement therapy, as defined in this
paper, has been shown to effectively reduce the incidence of
mineralocorticoid-related adverse events in patients with
mCRPC treated with abiraterone acetate (discussed below)
[4, 6]. Similarly, subjects with congenital CYP17A1 deficiency
produce excessive mineralocorticoids and develop hyperten-
sion and hypokalemia [20], which can be mitigated by glu-
cocorticoid replacementtherapy, includinglow-doseprednisone
or prednisolone [21]. The use of glucocorticoid replacement
to correct treatment-related steroid imbalances is similar to
the use of glucocorticoid replacement therapy for other forms
of acute or chronic adrenal insufficiency [22]. In these settings,
themain goal is tomimic normal cortisol production to restore
normal physiology while minimizing adverse effects. The
choice of glucocorticoid, its dose, and the treatment duration
are important considerations for achieving these goals [23].
Currently, abiraterone acetate is approved only for use in
combination with the prednisone or prednisolone dose given
orally (5 mg) in the morning and evening. Other regimens and
alternative glucocorticoids might be equivalent or superior
cotherapies for specific patients, but different regimens have
not been compared directly. There is an ongoing phase III
trial of abiraterone acetate with 5 mg/day of prednisone or
prednisolone in newly diagnosed patients with metastatic,
hormone-na¨ıve prostate cancer (ClinicalTrials.gov identifier
NCT01715285). In the phase I and II trials, abiraterone acetate
was administered without any glucocorticoid, and hyperten-
sion and hypokalemia were successfully managed with
the mineralocorticoid receptor antagonist eplerenone at an
average dose of 50 mg/day, often with addition of dexameth-
asone 0.5 mg/day on progression [13].
©AlphaMed Press 2014
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PHARMACOLOGIC EFFECTS OF LONG-TERM
GLUCOCORTICOID THERAPY
It is well recognized that glucocorticoids produce a variety of
adverse events when used for prolonged periods to treat
various autoimmuneand inflammatorydiseases, suchas rheu-
matoid arthritis, Crohn’s disease, and asthma, and various
cancers [23–26]. Glucocorticoid-related adverse events in-
clude altered bone metabolism, immunosuppression, in-
creased risk of hyperglycemia and diabetes, adverse impact
on mood and cognitive function, and muscle weakness. In
general, these glucocorticoid-related adverse events are
related primarily to the cumulative dose over a prolonged
treatment period or to use of high doses during short-term
exposure.
Glucocorticoidsmay inducebonemineral lossand increase
risk of osteoporosis and fracture after extensive exposure. In
rheumatoid arthritis, glucocorticoids increase risk of these
bone abnormalities beyond the risk associated with the
disease itself [26, 27]. In the British General Practice Research
Database, for example, the relative riskof hip fracturewas two
times higher among patients with versus without rheumatoid
arthritis, with the relative risk increasing to 3.4-fold among
those patients with rheumatoid arthritis receiving oral
glucocorticoids [26]. Based on studies in rheumatoid arthritis
and asthma, risk for bone mineral density reduction and/or
osteoporosis is significant with high-dose glucocorticoids
(.15 mg/day) and with glucocorticoid treatment at 7.5 mg/
day for longer periods (.6 months) [28]. In addition, the
Figure1. Abiraterone inhibitsCYP17A1,whichactsat twokeysynthetic steps inandrogenbiosynthesis.PrecursorsupstreamofCYP17A1-
catalyzed steps accumulate, resulting in mineralocorticoid excess [11].
Abbreviations: DHEA[-S], dehydroepiandrosterone [sulfate]; DHT, dihydrotestosterone.
Figure 2. Abiraterone acetate reduces serum androgens and serum cortisol as a result of blocking CYP17A1. Shown are the changes in
mean steroid levels from baseline to day 28 in patients with metastatic castration-resistant prostate cancer who received abiraterone
acetate at doses of 250, 500, 750, or 1,000 mg daily [8].
Abbreviation: DHEA-S, dehydroepiandrosterone sulfate.
www.TheOncologist.com ©AlphaMed Press 2014
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frequency of short-course oral glucocorticoid bursts has been
associated with reductions in bone mineral density and in-
creased risk of osteopenia in longitudinal studies in asthmatic
children treated for 3 years with a total follow-up of 7 years
and inadultswithmean treatment for7.7yearswithadditional
follow-up for a median of 4 years [29, 30].
For patients who have a set of autosomal recessive di-
seases known as congenital adrenal hyperplasia (CAH), long-
term disease management using glucocorticoid therapy often
negatively affects bone health andquality of life [31].Themost
common form of CAH is 21-hydroxylase deficiency (21OHD),
which is characterized by cortisol and aldosterone deficiency;
furthermore, theaccumulating cortisol precursorsareshunted
to other biosynthetic pathways, leading to adrenal androgen
excess [31]. These patients receive long-term glucocorticoid
andmineralocorticoid therapy, not only to replace the cortisol
andaldosteronedeficiency butalso to suppress ACTHand thus
adrenal androgenproduction.These regimens typically consist
of supraphysiologic divided doses of hydrocortisone or sub-
stitution with prednisone/prednisolone or dexamethasone.
A reduction in bone mineral density and a threefold increase
in osteopenia or osteoporosis was seen in adult male patients
with 21OHD aged .30 years versus age-matched controls,
with long-acting glucocorticoids more negatively affecting
bone health compared with short-acting glucocorticoids [32].
In this study, the majority of patients with 21OHD had normal
bone density, and the prevalence of diabetes mellitus was
not increased. As for asthma and inflammatory diseases, bone
loss in CAH patients is attributed specifically to a lifetime
of prolonged exposure to supraphysiologic glucocorticoids
necessary to control androgen excess. Optimized glucocorti-
coid therapy plus vitamin D and calcium supplementation
mitigate these consequences [31, 33]. In the mCRPC setting,
long-term glucocorticoid therapy warrants caution and
continuous monitoring, especially in frail elderly men who
may have significant comorbidities and prior cumulative
steroid exposure that may adversely affect their bone health.
Very frail patients with poor performance scores and short life
expectancies are excluded from most clinical trials, so ex-
trapolation of published studies to these populations should
be done with caution.
Glucocorticoids produce a number of metabolic effects,
most importantly hyperglycemiaand increased riskofdiabetes
mellitus. In a cohort of patients with rheumatic disease, the
development of diabetes was significantly correlated with the
cumulativeprednisonedoseover thecourseof treatment [34].
The mean cumulative dose for patients with steroid-induced
hyperglycemia was 26.6 g compared with 11.6 g for those
without steroid-inducedhyperglycemia [34].Given the limited
life expectancy of mCRPC patients, the anticipated steroid
exposure at a dose of 10 mg/day would be lower than these
levels (,4 g over 1 year). Moreover, the incidence of post-
transplant diabetes among renal transplant recipients main-
tained on prednisone 5–7.5 mg/day during a median 5-year
follow-up was 15%, which was significantly higher than the
incidence among those who did not have glucocorticoid
maintenance (5%) [35].
Glucocorticoids exert negative effects on mood and cog-
nitive function that, again, correlate with the dose and/or
length of treatment [36]. In a cohort of 27 children (aged 8–16
years) with severe asthma treated with prednisolone for,14
days, those given high doses (mean: 62mg/day) had increased
symptoms of anxiety and depression compared with those
receiving lowdoses (mean: 3mg/day) [36,37]. Ina cohortof20
adults with asthma or rheumatic disease receiving prednisone
at a mean dose of 19 mg/day for a mean duration of 128
months, 12 (60%) met diagnostic criteria for a prednisone-
induced mood disorder, most frequently depression, at some
point during treatment [38]. Changes in cognition are often
observed during glucocorticoid therapy, most commonly de-
creases in declarative (verbal) memory [36]. In the afore-
mentioned study in children with severe asthma, greater
decreases in declarative memory were reported with high
versus low glucocorticoid doses [36, 37]. Patients with asthma
often receive multiple medications in addition to glucocorti-
coids, and that might also contribute to effects on cognitive
function.
Minimal data are available for glucocorticoid-induced my-
opathy in prostate cancer, but generally a low incidence is ob-
served. Severe fatigue, myopathy, or muscle weakness were
not reported in a phase III trial of low-dose prednisone with or
without mitoxantrone in patients with asymptomatic CRPC
[39]. In the TAX 327 study, in which low-dose prednisone was
administered with either docetaxel or mitoxantrone, severe
fatigue was reported in 5% of patients, yet myopathy was not
reported [40]. Similarly, grade 3 fatigue was reported in 8% of
men with mCRPC after chemotherapy who received thalido-
mide plus oral dexamethasone [41]. In the COU-AA-302 trial of
Figure 3. Abiraterone increases steroids with mineralocorticoid activity upstream of CYP17A1. Shown are median serum levels of
corticosteroneanddeoxycorticosteroneover time inpatientswithmetastatic castration-resistant prostate cancerwho received abiraterone
acetate at doses of 250 to 2,000 mg daily. The right panel shows mean corticosterone levels at day 28 by abiraterone acetate dose [12].
©AlphaMed Press 2014
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chemotherapy-na¨ıve mCRPC patients [42], muscle weakness
was infrequently reported in 0.6%ofpatients in the abiraterone
acetate-plus-prednisone arm and in 1.1% of patients in the
prednisone-alone arm (data on file, Janssen Research & Devel-
opment, 2012). In other disorders, glucocorticoid-induced my-
opathy has been associated primarily with high-dose steroid
treatment, a sedentary lifestyle, and the use of fluorinated
steroids (e.g., triamcinolone, dexamethasone) rather than non-
fluorinated steroids (e.g., hydrocortisone, prednisone) [43, 44].
The glucocorticoid-induced myopathy is fully yet slowly revers-
ible when the dose is reduced below 30 mg/day of hydrocorti-
sone or its equivalent, with a rehabilitative conditioning
program appearing to be the most effective treatment [44].
Taken together, these findings indicate that the incidence
of glucocorticoid-induced adverse events—including bone
loss,diabetes, centralnervous systemeffects, andmyopathy—
are related to dose and choice of glucocorticoid, and these
consequences tend to occur at doses much higher than those
used in mCRPC [23]. When interpreting potential adverse
effects of glucocorticoids in an elderly population of menwith
prostate cancer, the patients’ comorbidities, family history,
and prior glucocorticoid and medication exposure should be
taken into account.
EFFECT OF PREDNISONE ON IMMUNE FUNCTION
Glucocorticoidshavebeencommonlyused incancer treatment,
although their immunosuppressive properties have always
been of specific concern [23]; nevertheless, the immunosup-
pressive properties may be seen at doses of glucocorticoids
above those recommended in approved therapeutic regimens
for prostate cancer (e.g., prednisone 10 mg/day). In vitro,
glucocorticoids stimulate macrophage function at low con-
centrations (e.g., 0.1 nM), including expression of proinflam-
matory cytokines and chemokines and production of nitric
oxide, whereas they suppress these functions at high con-
centrations (e.g., 1 mM) [45]. In an animal model, prednisone
did not affect the oxidative burst mediated by complement
receptors during neutrophil phagocytosis, even when admin-
istered for 7–15 days at a dose equivalent to 90 mg/day in
humans [46].
The systemic exposure attained with the recommended
low-dose glucocorticoids is below the amount shown to inhibit
immune cell proliferation in response to antigens. Pediatric pa-
tients treated with prednisone (2 mg/kg per day for 5 days,
or#0.5mg/kgperdayfor.6months) forchronic inflammatory
disorders, including juvenile idiopathic arthritis, systemic lupus
erythematosus, or asthma, showed an appropriate immune
response when immunized with influenza vaccine, successfully
demonstrating a protective antibody titer against influenza A
and B antigens [47, 48]. In addition, no flu-like symptoms were
noted in any of the children during the 6-month evaluation
period following vaccination [47]. Similarly, prednisone treat-
ment did not influence the immunogenicity of an influenza
vaccine in adults with rheumatoid arthritis [49], although
a recent report indicated that prednisone doses$10 mg/day
were associated with lower antibody responses in patients
with systemic lupus erythematosus [50].
The systemic exposure attained with the recom-
mended low-dose glucocorticoids is below the
amount shown to inhibit immune cell proliferation in
response to antigens.
The effect of low-dose glucocorticoids on immune re-
sponses to personalized peptide vaccination was evaluated in
a study of 11 mCRPC patients [51]. Most patients, particularly
Figure 4. Low-dose prednisolone yields the equivalent of phy-
siologic cortisol levels. Daily prednisolone (10 mg/day) with abi-
raterone acetate (1,000 mg/day) in 15 castration-resistant
prostate cancer patients led to median prednisolone concen-
trations of 152 nmol/L (solid line). Given an∼4:1 relative potency
of prednisolone:hydrocortisone, 152 3 4 is equivalent to 608
nmol/L cortisol, which is within physiologic concentrations [16].
Dotted line is 10 nmol/L.
Figure 5. Dexamethasone (0.5 mg/day) suppresses abiraterone-
mediated increases in adrenocorticotropic hormone (ACTH).
Abiraterone acetate treatment (n 5 26) was associated with
a significant increase inmedianplasmaACTH levels from17pg/mL
to124pg/mL (660% increase).This rise inACTHwas suppressed to
belowthe lower limitof sensitivity (10pg/mL)afteradministration
of oral dexamethasone 0.5 mg/day for ,14 days. Normal ACTH
levels in adults (mean6 SE): 28.76 12 [13, 17].
Abbreviations: ACTH, adrenocorticotropic hormone; LLOS,
lower limit of sensitivity; Rx, treatment.
www.TheOncologist.com ©AlphaMed Press 2014
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when treated concurrently with dexamethasone (1 mg/day)
or prednisolone (10 mg/day), were able to generate peptide-
specific immunoglobulin-G antibodies and cytotoxic T-cell
responses. These findings suggest that low-dose glucocorti-
coids in this study did not suppress immune responses to
tumor-specific peptides. Moreover, recent data suggest that
immune responses to sipuleucel-Twere successfully produced
in men with mCRPC when administered concurrently with
orprior to treatmentwithabirateroneacetateplusprednisone
[52]. Thus, although the immunosuppressive effects of glu-
cocorticoids have the potential to interfere with treatment
effects of immunotherapeutic agents, low doses of glucocorti-
coids do not appear to reduce immune responses to vac-
cination substantially. Nevertheless, it is essential to consider
the patient population (e.g., age, frailty, previous treatments)
when interpreting the effects of glucocorticoids on immune
function.
SAFETY PROFILE OF ABIRATERONE ACETATE
COADMINISTERED WITH PREDNISONE
Abiraterone acetate (1,000 mg) coadministered with pred-
nisone (5 mg twice daily) was compared with placebo plus
prednisone in patients with mCRPC in two phase III, multi-
national, double-blind, randomized, placebo-controlled tri-
als. StudyCOU-AA-301comprised1,195patientswithmCRPC
who had progressed after docetaxel treatment [4], and study
COU-AA-302 involved 1,088 patients with mCRPC who had
not received chemotherapy and who did not have clinically
significant cancer-related symptoms (i.e., asymptomatic or
minimally symptomatic patients) [5]. Both studies evaluated
treatment effects on survival and disease progression,
showing clinically meaningful and significant benefits in
favor of abiraterone acetate plus prednisone [5, 15]. On the
basis of the results from these studies, abiraterone acetate
in combination with prednisone was approved for the
treatment of patients with mCRPC.
COU-AA-301 and COU-AA-302 also thoroughly assessed
safety and tolerability, and these studies demonstrated that
the safety profile of abiraterone acetate plus prednisone was
comparable to that observed in earlier clinical studies [6, 8]. In
both studies, adverse events associated with mineralocorti-
coid activity were more common for abiraterone acetate plus
prednisone than for prednisone alone (Fig. 6) [4, 5], but their
incidencewas largely abrogatedby low-doseprednisonewhen
compared with earlier studies of abiraterone acetate mono-
therapy [8, 12, 53]. Notably, themajority ofmineralocorticoid-
related adverse events were grade 1 or 2 in severity. With
coadministration of abiraterone acetate and prednisone in
COU-AA-301, the incidence of mineralocorticoid excess-
related severe adverse events, including hypertension
(1.3% vs. 0.3%), hypokalemia (4.4% vs. 0.8%), and fluid
retention or edema (2.5% vs. 1.0%), was low and manageable
[15].The incidence of these severe adverse events in COU-AA-
302was also low, and the difference between treatment arms
was even less apparent (hypertension, 3.9% vs. 3.0%;
hypokalemia, 2.4% vs. 1.9%; fluid retention or edema, 0.7%
vs. 1.7%) [5].
The discontinuation rate for abiraterone acetate and
prednisone in COU-AA-301 and COU-AA-302 was low, and side
effects were easily manageable and reversible, despite the
advanced age and advanced disease states of the study pop-
ulations [5, 15]. Exposure to prednisone across treatment
groupswas relatively short,withamedianof7.4months (range:
0.2–25.6 months) in COU-AA-301 [15]. In COU-AA-302, no
glucocorticoid-related adverse events greater than those in
COU-AA-301 were observed despite a longer median duration
(13.8 months) of abiraterone acetate-prednisone cotreatment
[15, 42]. In the latter study, nonewsafety signalswereobserved
in the subset of patients who received abiraterone acetate
plus prednisone or prednisone alone for $24 months, with
cumulative incidence rates of selected adverse events in-
cluding fatigue, hypertension, osteoporosis, and hyperglycemia
remaining similar between treatment groups [42]. Rates
of infection were comparable in both groups during long-
term treatment. Taken together, results from COU-AA-301
and COU-AA-302 provide proof of principle that low-dose
prednisone can be delivered safely without any consistent
additional serious adverse effects while adequately managing
Figure 6. Incidence ofmineralocorticoid-related adverse events inmetastatic castration-resistant prostate cancer patients treatedwith
abiraterone acetate plus prednisone compared with placebo plus prednisone in the COU-AA-301 and COU-AA-302 phase III randomized
controlled studies [5, 15].
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mineralocorticoid-related adverse events resulting from
CYP17A1 inhibition by abiraterone.
THERAPEUTIC OR ADJUNCTIVE USE OF GLUCOCORTICOIDS
IN MCRPC
Glucocorticoids are often given to cancer patients tomanage
tumor-related symptoms, such as bone pain or weight loss,
and to alleviate toxic effects associated with specific cancer
treatments, such as nausea, vomiting, edema, and hyper-
sensitivity reactions related to chemotherapy [23]. Gluco-
corticoids are also used in specific situations, such as pain
palliation and to reduce swelling from cord compression or
radiation of brain metastases. Tumor-related cachexia was
infrequent in the abiraterone acetate studies. Although
megestrol acetate is better tolerated than dexamethasone
[54], megestrol acetate at high doses acts as a glucocorticoid
receptor modulator and causes adrenal axis suppression
[54], which necessitates glucocorticoid treatment if patients
undergo a stress-related condition, including trauma, in-
fection, or surgery. Glucocorticoids are a viable and less
expensive alternative tomegestrol acetate for tumor-related
cachexia in those with a history of thromboembolic com-
plications or other contraindication.
Low-dose glucocorticoids might also offer therapeutic
benefits, albeit relativelymodest, as demonstrated by results
ofseveral retrospectiveanalysesandarandomizedtrial showing
prostate-specific antigen response rates of 22%–61% [56–58]
and by results from the placebo-prednisone arms of COU-AA-
301 and COU-AA-302 [4, 5]. Particularly in COU-AA-302, low-
dose prednisone behaved as an active comparator, producing
objective responses defined by Response Evaluation Criteria
in Solid Tumors in 16% of patients and a $50% decline in
prostate-specificantigen levels in24%ofpatients [5].Although
not the subject of this review, theobservations of therapeutic
benefit in mCRPC contradict results of preclinical studies
that suggest glucocorticoids may have the potential to
driveprostate cancerprogression [59].Glucocorticoidsmight
also drive tumor growth via mutant androgen receptors,
based on preclinical data showing that the H874Y and T877S
androgen receptor mutations are weakly responsive to
cortisol and dexamethasone at micromolar concentrations
[60].
ADDITIONALPRACTICALCAVEATS ANDCONSIDERATIONS FOR
GLUCOCORTICOID USE
Decisions regarding which glucocorticoid to use at what
dose and for how long should take into consideration
several physiologic factors.When personalizing glucocorti-
coid replacement therapy, it is important to recognize how
differences in glucocorticoid metabolism might affect
individual patient responses. Hepatic 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) is essential for the
conversion of inactive oral glucocorticoid prodrugs like
prednisone and cortisone to their active 11b-hydroxy
derivatives prednisolone and cortisol [61]. Glucocorticoid
conversion catalyzed by 11b-HSD1 is bidirectional, but its
predominant action in vivo is conversion of inactive to active
glucocorticoids [62]. Patients who have decreased 11b-
HSD1 enzymatic activity, and in rare cases lack the 11b-
HSD1 enzyme, might not respond to prednisone because
they are unable to generate a substantial amount of
prednisolone [63]. In such cases, in patients with liver
metastases or impaired hepatic function, prednisolone
might be the better alternative for glucocorticoid replace-
ment therapy because it does not depend on metabolic
conversion.
Table 1. Mineralocorticoid-related adverse events in abiraterone acetate-treated patients in the COU-AA-302 and COU-AA-301
registrational trials with coadministered prednisone (North American sites) versus prednisolone (European Union sites).
Adverse
event
COU-AA-302 COU-AA-301
AA plus
prednisone
(n5 354)
Prednisone
(n5 345)
AA plus
prednisolone
(n5 188)
Prednisolone
(n5 195)
AA plus
prednisone
(n5 334)
Prednisone
(n5 159)
AA plus
prednisolone
(n5 457)
Prednisolone
(n5 235)
All grades, n (%)
Fluid retention/
edema
118 (33.3) 99 (28.7) 40 (21.3) 31 (15.9) 112 (33.5) 34 (21.4) 148 (32.4) 60 (25.5)
Hypokalemia 67 (18.9) 45 (13) 26 (13.8) 24 (12.3) 56 (16.8) 15 (9.4) 87 (19.0) 21 (8.9)
Hypertension 79 (22.3) 37 (10.7) 39 (20.7) 36 (18.5) 40 (12.0) 14 (8.8) 48 (10.5) 11 (4.7)
Grades1and2,n (%)
Fluid retention/
edema
114 (32.2) 93 (27) 39 (20.7) 28 (14.4) 102 (30.5) 34 (21.4) 138 (30.2) 55 (23.4)
Hypokalemia 57 (16.1) 39 (11.3) 22 (11.7) 20 (10.3) 37 (11.1) 14 (8.8) 71 (15.5) 19 (8.1)
Hypertension 63 (17.8) 27 (7.8) 32 (17) 29 (14.9) 36 (10.8) 13 (8.2) 42 (9.2) 18 (7.7)
Grades3and4,n (%)
Fluid retention/
edema
4 (1.1) 6 (1.7) 1 (0.5) 3 (1.5) 10 (3) 0 (0) 10 (2.2) 4 (1.7)
Hypokalemia 10 (2.8) 6 (1.7) 4 (2.1) 4 (2.1) 19 (5.7) 1 (0.6) 16 (3.5) 2 (0.9)
Hypertension 16 (4.5) 10 (2.9) 7 (3.7) 7 (3.6) 4 (1.2) 1 (0.6) 6 (1.3) 0 (0)
Abbreviation: AA, abiraterone acetate.
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Patients who have decreased 11b-HSD1 enzymatic
activity, and in rare cases lack the 11b-HSD1
enzyme, might not respond to prednisone because
they are unable to generate a substantial amount of
prednisolone.
To indirectly compare the use of prednisone or predniso-
lone in combination with abiraterone acetate, we compared
the safety profile related to mineralocorticoid excess in COU-
AA-301 or COU-AA-302 among patients enrolled at North
American versus European Union sites. Prednisone and
prednisolone were coadministered with abiraterone acetate
at the North American and European Union sites, respectively.
The data suggest a lower incidence of mineralocorticoid-
related adverse events with prednisolone (10 mg) versus
prednisone (10 mg) coadministered with abiraterone acetate
(Table 1). This apparently lower incidence of events with
prednisolone compared with prednisone was observed for
grade 3 or 4 fluid retention or edema and hypokalemia in both
studies and for grade 3 or 4 hypertension in COU-AA-302 but
not in COU-AA-301. These data suggest that switching from
prednisone to prednisolone might be a beneficial approach in
patients who are more sensitive to abiraterone acetate-
inducedmineralocorticoid-relatedeventsasaconsequenceof
deficient11b-HSD1activity, suchaspatientswith concomitant
liver disease. Additional studies would be required to test this
hypothesis directly.
Some glucocorticoid-related adverse events might be of
lesser concern in patients with mCRPC compared with the
general population; this reflects disease consequences or
previous therapeutic interventions. Patients with mCRPC
also are not likely to have received pancreatic b-cell-
damaging chemotherapeutic regimens, which could influ-
ence the incidence and magnitude of hyperglycemia when
glucocorticoids are used [64]. In addition, consequences of
treatment-induced hyperglycemia need to be placed in the
context of the reduced life expectancy of the mCRPC pop-
ulation [65]. Finally, patients withmCRPC, a populationmore
prone to fractures due to prior androgen deprivation therapy
and increased risk of bone metastasis, are often given prophy-
lactic vitamin D and/or calcium supplements and bisphosp-
honates, and these treatments attenuate bone loss in this
setting [66].
Most patients withmCRPC, particularly thosewith disease
progression following docetaxel or hormone suppression
therapy, already receive glucocorticoid therapy to manage
disease-related symptoms [40, 67, 68]. In cases for which
glucocorticoids are not being used, physicians and patients
should discuss the benefits versus the risks of glucocorticoid
use, including potential short-term and long-term effects. If
a decision is made to start glucocorticoid therapy, patients
should be monitored regularly to determine whether treat-
ment is providing the desired effects (e.g., minimizing
mineralocorticoid-related adverse events associated with
abiraterone acetate) and tomonitor for glucocorticoid-related
adverse events. Although such adverse events have been
observed in some patients receiving low-dose glucocorticoids,
these consequences are typically associated with higher
exposure of cumulative long-term dosing.
CONCLUSION
Glucocorticoid replacement therapy with low-dose predni-
sone substitutes for reduced cortisol levels, lowers ACTH
levels, and in turn reduces the incidence and severity of
mineralocorticoid-related adverse events in mCRPC patients
treated with abiraterone acetate. The dose of prednisone
indicated with abiraterone acetate and the glucocorticoid
dosesused inother treatment regimens formCRPCare low (10
mg/day prednisone equivalence) compared with the thera-
peutic glucocorticoid doses used to treat other malignancies
and in autoimmune disorders (typically $20 mg/day predni-
soneequivalence). It is these latterhigherdosesthathavebeen
consistently associated with an adverse safety profile. Avail-
able data suggest that prednisone, when given in low doses,
exerts little effect on immune function and that safe and
efficacious coadministration with immunomodulatory agents
is possible. Nevertheless, further evaluation of the long-term
safety profile of low-dose glucocorticoids for patients with
mCRPC is warranted, given the improvements in survival
achieved with progressive lines of glucocorticoid-containing
regimens. These evaluations need to take into consideration
the patient-specific factors such as physiologic status, in-
cluding ability to metabolize prednisone; comorbidities; and
length of androgen suppression. Simultaneously, the risks
associated with the adverse effects of glucocorticoids in
mCRPCmust be balanced by considering all potential benefits,
including pain relief and quality of life.
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